Home> Trial Details

Information Clinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.Learn why

Optimise reading forHealth Professionals Patients

RecruitingLast updated:29 August 2023

SPARTA: This trial is trying to understand how safe and tolerable a new oral treatment (APL-101) is for patients with non-small cell lung cancer and other advanced cancersPhase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Clinical summary Eligibilty Participating hospital Support

Clinical summary

Summary

The Phase 2 portion of this trial is now open for people with Non-Small Cell Lung Cancer and other advanced cancers with Exon 14 skip mutations and MET-dysregulations. Participants will receive will receive the recommended Phase 2 dose (RP2D) of APL-101 at 400mg daily dose (200mg twice a day).

Age

People 18+

Phase

Trial Acronym

SPARTA

More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

NCT03175224
APL-101-01

Commercial Sponsor

Apollomics Inc.

Scientific Title

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Share with email